Xencor, Inc. (XNCR)
| Market Cap | 839.28M +40.8% |
| Revenue (ttm) | 97.36M -23.5% |
| Net Income | -172.42M |
| EPS | -2.31 |
| Shares Out | 74.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 904,276 |
| Open | 10.49 |
| Previous Close | 10.41 |
| Day's Range | 10.49 - 11.38 |
| 52-Week Range | 6.92 - 18.69 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 28.50 (+151.77%) |
| Earnings Date | May 6, 2026 |
About XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase... [Read more]
Financial Performance
In 2025, Xencor's revenue was $125.58 million, an increase of 13.65% compared to the previous year's $110.49 million. Losses were -$91.92 million, -60.48% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for XNCR stock is "Buy." The 12-month stock price target is $28.5, which is an increase of 151.77% from the latest price.
News
Xencor Transcript: Bank of America Global Healthcare Conference 2026
A rapid cadence of clinical data is expected across oncology and autoimmune programs, with XmAb819 and XmAb942 as key near-term value drivers. Strategic focus is on advancing wholly owned assets, leveraging innovative bispecific technologies and a disciplined, data-driven approach to investment and development.
Xencor Slides: Corporate presentation
Xencor has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Xencor price target raised to $14 from $13 at JPMorgan
JPMorgan raised the firm’s price target on Xencor (XNCR) to $14 from $13 and keeps a Neutral rating on the shares.
Xencor reports Q1 EPS ($1.71), consensus (75c)
“Xencor (XNCR) continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease. We look forward to presenting expansion cohort data fr...
Xencor Reports First Quarter 2026 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...
Xencor Earnings release: Q1 2026
Xencor released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Xencor Quarterly report: Q1 2026
Xencor has published its Q1 2026 quarterly earnings report on May 6, 2026.
Xencor Transcript: Digestive Disease Week Conference
Phase I data for XmAb942 showed high potency, long half-life, and low immunogenicity, supporting infrequent dosing in ulcerative colitis. XmAb412, a bispecific targeting TL1A and IL-23p19, is set for Phase I in Q3 2026, with both programs aiming for pivotal data in 2027.
Xencor Slides: Digestive Disease Week Conference
Xencor has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Xencor to host webcast to discuss XmAb942, XmAb412 data presentations
Xencor (XNCR) reported final results from the Phase 1 study of XmAb942, a novel, potential best-in-class, long-acting anti-TL1A antibody for the treatment of inflammatory bowel disease. The results ar...
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...
Xencor Proxy statement: Proxy filing
Xencor filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Xencor Proxy statement: Proxy filing
Xencor filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
JPMorgan downgrades Xencor on lack of ‘needle-moving’ catalysts
JPMorgan downgraded Xencor (XNCR) to Neutral from Overweight with a price target of $13, down from $18. The firm sees 2026 as more of a clinical execution year for Xencor.
Xencor downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Xencor (XNCR) to Neutral from Overweight with a price target of $13, down from $18. The firm views the company’s 2026 as an “execution year.” Xencor’s pipeline will…
Xencor Transcript: Barclays 28th Annual Global Healthcare Conference
The discussion highlighted progress in oncology and immunology pipelines, with pivotal trial plans for lead T-cell engagers in 2027 and robust data supporting expansion into earlier therapy lines. Long-acting TL1A and bispecific programs in IBD aim for best-in-class efficacy and broad market reach.
Xencor Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a robust pipeline of bispecific antibodies in oncology and autoimmune diseases, with key programs XmAb819 and XmAb541 progressing toward pivotal trials and market expansion into new tumor types. Autoimmune efforts focus on TL1A-targeting molecules, with significant data updates expected in 2024.
Xencor reports receipt of notice of termination of license agreement from Roche
In a regulatory filing, Xencor (XNCR) disclosed that on March 4, the company received a notice of termination of an Amended and Restated Collaboration and License Agreement, effective as of…
Xencor expects cash to fund operations into mid-2028
Xenco announced that Alexion Pharmaceuticals informed Xencor (XNCR) that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris in the United…
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor Transcript: TD Cowen 46th Annual Health Care Conference
The organization is advancing a robust pipeline in oncology and autoimmune diseases, highlighted by pivotal studies for XmAb819 and XmAb942, and innovative programs like XmAb412 and XmAb657. Strong financials and strategic partnerships support clinical execution and future growth.
Xencor price target raised to $27 from $26 at Barclays
Barclays raised the firm’s price target on Xencor (XNCR) to $27 from $26 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q4…
Xencor files automatic mixed securities shelf
16:31 EST Xencor (XNCR) files automatic mixed securities shelf
Xencor reports Q4 EPS (9c), consensus (58c)
Reports Q4 revenue $28.2M, consensus $30M. “Xencor’s (XNCR) lead oncology drug candidate is XmAb819, a novel first-in-class T-cell engager that could offer a much-needed new therapeutic modality for p...
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...